Helius files FDA 510(k) for PoNS stroke label expansion; CEO/CFO get $1.5M bonuses that offset severance

Solana Co

FDA 510(k) filed for PoNS stroke label expansion under Breakthrough Device Designation.
Primary FGA endpoint met: mean improvement >5 points, p<0.05; control <4 points, below MDC.
CEO Andreeff gets $890k cash bonus; CFO Mathiesen gets $610k; both offset severance, change-in-control claims.
Bonuses settle any change-in-control claims from September 18, 2025 offerings.
Data from 159 chronic stroke patients across 10 sites; safety confirmed with no SAEs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.